28
Participants
Start Date
October 31, 2007
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2009
lenalidomide
Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
Department of Hematology, Rigshospitalet, Copenhagen
Department of Hematology, Herlev Hospital, Herlev
Department of Hematology, Odense University Hospital, Odense
Department of Hematology, Trondheim University Hospital, Trondheim
Department of Hematology, Vejle Hospital, Vejle
Department of Hematology, Aarhus University Hospital, Aarhus
Department of Hematology, Aalborg Hospital, Aalborg
Department of Hematology, Rikshospitalet University Hospital, Oslo
Department of Medicine, Ullevål Hospital, Oslo
Department of Hematology and Coagulation, Sahlgrenska University hospital, Gothenburg
Department of Hematology, Lund University Hospital, Lund
Department of Hematology, Malmö University Hospital, Malmo
Department of Medicine, Örebro University Hospital, Örebro
Hematology Center, Karolinska University Hospital Huddinge, Stockholm
Hematology Center, Karolinska University Hospital Solna, Stockholm
Department of Medicine, Sundsvall Hospital, Sundsvall
Department of Medicine, Umeå University Hospital, Umeå
Department of Hematology, Akademiska University Hospital, Uppsala
Nordic MDS Group
NETWORK